Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP). In current clinical practice, both single-session and multiple-session PRP approaches are widely accepted and utilized. The purpose of this study is to compare the safety and effectiveness of single-session and multiple-session PRP.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Central subfield retinal thickness (CRT)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Vessel Perfusion Density (VPD)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Vessel Length Density (VLD)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Foveal Avascular Zone (FAZ)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Lesion size
Timeframe: Baseline and 1, 3 and 6 months after treatment
Macular volume
Timeframe: Baseline and 1, 3 and 6 months after treatment
Venular saturation
Timeframe: Baseline and 1, 3 and 6 months after treatment
Imadeddin Abu Ishkheidem, M.D.
Arteriolar saturation
Timeframe: Baseline and 1, 3 and 6 months after treatment
Retinal diameter
Timeframe: Baseline and 1, 3 and 6 months after treatment
Venular diameter
Timeframe: Baseline and 1, 3 and 6 months after treatment
Retinal function
Timeframe: Baseline and 1, 3 and 6 months after treatment
Diabetic macular edema (DME)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Subjective experience of pain after treatment
Timeframe: Baseline and 1, 3 and 6 months after treatment
Subjective overall experience of the treatment
Timeframe: Baseline and 1, 3 and 6 months after treatment
Cost-effectiveness
Timeframe: Baseline and 1, 3 and 6 months after treatment